Kymeta Welcomes Industry Leaders to Board of Advisors
14.1.2025 17:00:00 CET | Business Wire | Press release
The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/
(Graphic: Business Wire)
The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private sector teams on scalability, agility, innovation, teamwork, talent development, and leadership.
“Having dedicated much of my career to serving our nation and leading teams in complex, high-stakes environments, I am deeply honored to join Kymeta as a Board Advisor,” stated James Geurts. “Their commitment to innovation, operational excellence, and leadership aligns closely with the principles I have upheld throughout my service. I look forward to contributing my experience and insights to help drive the company's continued growth and success in serving its customers, stakeholders, and communities.”
Elizabeth (Beth) Kimber is a 37-year veteran of the Central Intelligence Agency (CIA) who culminated her career as the Deputy Director of CIA for Operations (DDO) and oversaw CIA’s worldwide HUMINT operations and covert action missions. She also served as Acting Deputy Director of CIA; Assistant Director of CIA for Europe and Eurasia; Deputy Director of the National Clandestine Service, and Chief, Special Operations Department, Counterterrorism Center. She spent 18 years in the field including in assignments as Chief of Station / DNI Representative. In 2022, Kimber joined Two Six Technologies as Vice President of Intelligence Community Strategy. She also serves on the ManTech Board of Directors.
“Having spent a career supporting national security, I am honored to be a part of Kymeta’s Board of Advisors and help showcase their cutting-edge technologies and solutions to national security partners,” said Elizabeth Kimber. “Kymeta has demonstrated a steadfast commitment to innovation, integrity, and driving meaningful impact in its industry. I look forward to leveraging my experience in intelligence, risk management, and organizational leadership to support the company’s mission and help guide its continued growth and success in an ever-evolving world.”
“We are thrilled to welcome Elizabeth and James to our Board of Advisors,” said Rick Bergman, CEO and President, Kymeta. “Their voice and expertise are perfectly suited for helping Kymeta advance our vision of securing the future with innovative technology. Their extensive backgrounds in defense and space sectors are perfectly suited to help guide our business to the next phase of growth.”
About Kymeta
Kymeta revolutionizes satellite communications through Intelligent Communications Platforms (ICPs). Founded in 2012 and headquartered in Redmond, Washington, Kymeta leverages cutting-edge metamaterial-based science to engineer, manufacture and deliver resilient connectivity and enhanced situational awareness for critical, mobile applications. Backed by U.S. and international patents our electronically steered flat panel antennas enable seamless communications on-the-move. With software-defined solutions, hybrid multi-network capabilities, and edge processing, we integrate satellite and cellular networks, ensuring continuous connectivity in challenging environments. Kymeta solutions serve government, military, maritime, transport, and public safety clients worldwide, providing uninterrupted connectivity and spatial intelligence anywhere, anytime. With over 150 patents, Kymeta is shaping the future of global communications, dedicated to delivering reliable, efficient, and intelligent connectivity solutions for an increasingly mobile and connected world.
For more information, visit kymetacorp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114298718/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom